Table 5 Treatment-emergent adverse events (aes) ≥ grade 3, worst grade occurring in at least two subjects overall
Preferred term, n (%) | TAC + Bevacizumab (n = 92) | TCH + Bevacizumab (n = 34) | Total (N = 126) |
|---|---|---|---|
Subjects with at least one AE ≥ grade 3 | 62 (67.4) | 21 (61.8) | 83 (65.9) |
Neutropenia | 37 (40.2) | 3 (8.8) | 40 (31.7) |
Leukopenia | 16 (17.4) | 2 (5.9) | 18 (14.3) |
Fatigue | 6 (6.5) | 5 (14.7) | 11 (8.7) |
Thrombocytopenia | 5 (5.4) | 5 (14.7) | 10 (7.9) |
Hypertension | 6 (6.5) | 4 (11.8) | 10 (7.9) |
Abdominal pain | 4 (4.3) | 0 | 4 (3.2) |
Pain | 4 (4.3) | 0 | 4 (3.2) |
Nausea | 3 (3.3) | 1 (2.9) | 4 (3.2) |
Febrile neutropenia | 4 (4.3) | 0 | 4 (3.2) |
Headache | 1 (1.1) | 2 (5.9) | 3 (2.4) |
Dyspnea | 3 (3.3) | 0 | 3 (2.4) |
Clinical cardiac failure congestive | 3 (3.3) | 0 | 3 (2.4) |
Diarrhea | 1 (1.1) | 1 (2.9) | 2 (1.6) |
Arthralgia | 2 (2.2) | 0 | 2 (1.6) |
Vomiting | 2 (2.2) | 0 | 2 (1.6) |
Decreased appetite | 1 (1.1) | 1 (2.9) | 2 (1.6) |
Hot flush | 1 (1.1) | 1 (2.9) | 2 (1.6) |
Oropharyngeal pain | 2 (2.2) | 0 | 2 (1.6) |
Anxiety | 2 (2.2) | 0 | 2 (1.6) |
Neuropathy peripheral | 2 (2.2) | 0 | 2 (1.6) |
Back pain | 0 | 2 (5.9) | 2 (1.6) |
Asthenia | 1 (1.1) | 1 (2.9) | 2 (1.6) |
Hyperglycemia | 1 (1.1) | 1 (2.9) | 2 (1.6) |
Weight decreased | 2 (2.2) | 0 | 2 (1.6) |
Proteinuria | 1 (1.1) | 1 (2.9) | 2 (1.6) |
Neutrophil count decreased | 2 (2.2) | 0 | 2 (1.6) |
Postoperative wound infection | 2 (2.2) | 0 | 2 (1.6) |